JP2022078948A - 乳酸菌発酵産物含有外傷外用組成物 - Google Patents
乳酸菌発酵産物含有外傷外用組成物 Download PDFInfo
- Publication number
- JP2022078948A JP2022078948A JP2021146802A JP2021146802A JP2022078948A JP 2022078948 A JP2022078948 A JP 2022078948A JP 2021146802 A JP2021146802 A JP 2021146802A JP 2021146802 A JP2021146802 A JP 2021146802A JP 2022078948 A JP2022078948 A JP 2022078948A
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- carrier
- acid bacterium
- external composition
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 52
- 230000004151 fermentation Effects 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000029663 wound healing Effects 0.000 title abstract description 27
- 241000186660 Lactobacillus Species 0.000 title abstract 5
- 229940039696 lactobacillus Drugs 0.000 title abstract 5
- 241000894006 Bacteria Species 0.000 claims abstract description 55
- 239000000047 product Substances 0.000 claims abstract description 40
- 239000000706 filtrate Substances 0.000 claims abstract description 26
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 6
- 230000035876 healing Effects 0.000 claims abstract description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 104
- 235000014655 lactic acid Nutrition 0.000 claims description 52
- 239000004310 lactic acid Substances 0.000 claims description 52
- 230000000472 traumatic effect Effects 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 18
- 229920001817 Agar Polymers 0.000 claims description 13
- 239000008272 agar Substances 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 239000001968 M17 agar Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000000416 hydrocolloid Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000012827 research and development Methods 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 abstract description 24
- 230000002745 absorbent Effects 0.000 abstract description 9
- 239000002250 absorbent Substances 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 206010052428 Wound Diseases 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000969 carrier Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000020245 plant milk Nutrition 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229920002444 Exopolysaccharide Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- SERLAGPUMNYUCK-URHLDCCQSA-N (2R,3S,4R,5S)-6-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-URHLDCCQSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 229920001755 Kefiran Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
1.実験動物
まず、国家動物実験中心由来の、12匹の8~10週齢のC57BL/6J雄性マウスを、嘉義長庚病院動物中心で飼育し、動物飼育室の温度を22±2℃に維持し、相対湿度を62±5%にし、光周期を12時間明/12時間暗に調整し、毎日に飼育者により温湿度をモニターして記録した。飼料及び滅菌逆浸透水の両方がマウスによって自由に摂取されるようにした。飼育1週間後に、実験を開始した。
マウスについて、背側の皮膚を剃毛した後で、ベタジン溶液で皮膚を消毒し、まず、シリカゲルで副木をマウスの両側に固定してから、手術的外傷創傷によって1cm*1cm面積の皮膚を除去し、深さ約4~5mmの創傷にし、外傷の1時間後に、マウスを群分けし、生理食塩水群(n=6)及びGKM3発酵濾液群(n=6)に分け、合計で12匹のマウスであった。被覆材を連続に投与し、それぞれ創傷形成後の0、2、4、6、8、10日目に動物創傷修復度を観察して、創傷の修復面積の算出や換算を行った。安全性指標で実験動物の健康に無害であると判定する場合、被験物を投与した後で、本実験では、手術後の3日に毎日筋肉注射するように1mg/kgの用量で鎮痛剤を投与し、2日毎に被覆材を交換し、創傷治癒状況を撮影して面積を算出し、その結果が図1及び図2に示された。
本実験では、マウス皮膚に同一範囲及び同一程度の創傷を作り、それぞれ生理食塩水(制御群)及び益生菌GKM3発酵濃縮濾液(GKM3群)を投与し、マウスに対して創傷治癒状況を10日観察した。益生菌GKM3発酵濃縮濾液としては、GKM3によってMRS培養液を16時間発酵させた後、遠心工程を行って菌体を除去して、得られた上清液を減圧濃縮して10倍濃縮したものであり、発酵基質の初期体積の10%まで濃縮したものに相当していた。
植物乳杆菌(Lactobacillus plantarum)GKM3は、台湾新竹食品路331号である中華民国財団法人食品工業発展研究所生物資源保存及び研究中心に寄託され、寄託日は2017年7月14日であり、寄託番号はBCRC910787であり、2017年7月26日にこの菌株が生存していることが確認された。
Claims (7)
- 乳酸菌によって発酵基質に対して発酵工程、固液分離工程及び濃縮工程を行って得られ且つ菌体を含まない濃縮濾液であり、且つ前記乳酸菌は植物乳杆菌(Lactobacillus plantarum)GKM3(台湾新竹食品路331号である中華民国財団法人食品工業発展研究所生物資源保存及び研究中心に寄託され、寄託日は2017年7月14日であり、寄託番号はBCRC910787である)である、有効成分としての乳酸菌発酵産物と、
前記有効成分を搭載する薬学的に受容可能な吸収性担体又はキャリアと、
を含む乳酸菌発酵産物含有外傷外用組成物。 - 前記発酵基質は、MRS寒天、PCA寒天、M17寒天、Rogosa寒天、TOS-MUP寒天及びそれらの如何なる組み合わせからなる群から選ばれる請求項1に記載の乳酸菌発酵産物含有外傷外用組成物。
- 前記濃縮濾液は、前記発酵基質の初期体積の5%~20%まで濃縮される請求項1又は2に記載の乳酸菌発酵産物含有外傷外用組成物。
- 前記吸収性担体は、ファイバー担体、通気フィルム担体、ヒドロコロイド担体、ゲル担体、フォーム担体、アルゲコロイド担体、タンパク質担体及びそれらの如何なる組み合わせからなる群から選ばれる請求項1~3の何れか1項に記載の乳酸菌発酵産物含有外傷外用組成物。
- 前記キャリアはエアロゾル化剤を含み、且つ前記外傷外用組成物はエアゾールである請求項1~3の何れか1項に記載の乳酸菌発酵産物含有外傷外用組成物。
- 前記乳酸菌発酵産物は、皮膚外傷に対して抗炎症及び治癒促進という効果を持つ請求項1~5の何れか1項に記載の乳酸菌発酵産物含有外傷外用組成物。
- 前記有効成分は、薬学的成分を更に含む請求項1~6の何れか1項に記載の乳酸菌発酵産物含有外傷外用組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW109139743A TWI825362B (zh) | 2020-11-13 | 2020-11-13 | 乳酸菌醱酵產物用於製備促進皮膚創傷癒合之外用組成物的用途 |
TW109139743 | 2020-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022078948A true JP2022078948A (ja) | 2022-05-25 |
JP7297021B2 JP7297021B2 (ja) | 2023-06-23 |
Family
ID=81588473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021146802A Active JP7297021B2 (ja) | 2020-11-13 | 2021-09-09 | 乳酸菌発酵産物含有外傷外用組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11766465B2 (ja) |
JP (1) | JP7297021B2 (ja) |
TW (1) | TWI825362B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114470007A (zh) * | 2020-11-13 | 2022-05-13 | 葡萄王生技股份有限公司 | 含乳酸菌发酵产物之创伤外用组合物及其用途 |
CN116948921B (zh) * | 2023-09-19 | 2023-12-26 | 黑龙江省科学院微生物研究所 | 植物乳杆菌及其外泌体的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106573023A (zh) * | 2014-08-13 | 2017-04-19 | 雀巢产品技术援助有限公司 | 植物乳杆菌cncm i‑4026制备物及其皮肤健康益处 |
TW201917206A (zh) * | 2017-10-20 | 2019-05-01 | 葡萄王生技股份有限公司 | 一種胚芽乳酸桿菌、組合物、培養方法及降尿酸、改善過敏及/或降血糖的用途 |
JP2019214548A (ja) * | 2018-04-24 | 2019-12-19 | 葡萄王生技股▲分▼有限公司 | 骨疾患を予防、治療又は軽減するための方法及び組成物 |
JP2020059694A (ja) * | 2018-08-16 | 2020-04-16 | 葡萄王生技股▲ふん▼有限公司 | 長寿促進のための、ラクトバチルス・プランタルムgkm3の活性物質、それを含む組成物、およびその使用 |
WO2020106099A1 (ko) * | 2018-11-22 | 2020-05-28 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
JP2020080861A (ja) * | 2018-11-21 | 2020-06-04 | 葡萄王生技股▲ふん▼有限公司 | ラクトバチルスファーメンタムgkf3、それを含む組成物及び精神失調を改善する適用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3327840C1 (de) * | 1983-08-02 | 1984-09-20 | Blendax Werke Schneider Co | Hautpflegemittel |
TWI636134B (zh) * | 2017-10-20 | 2018-09-21 | 葡萄王生技股份有限公司 | 一種胚芽乳酸桿菌、組合物、培養方法及降血脂及/或降低肝功能指數的用途 |
TWI718402B (zh) * | 2018-08-16 | 2021-02-11 | 葡萄王生技股份有限公司 | 副乾酪乳酸桿菌gks6之活性物質、含其之組合物及其促進長壽之用途 |
-
2020
- 2020-11-13 TW TW109139743A patent/TWI825362B/zh active
-
2021
- 2021-09-09 JP JP2021146802A patent/JP7297021B2/ja active Active
- 2021-10-29 US US17/514,670 patent/US11766465B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106573023A (zh) * | 2014-08-13 | 2017-04-19 | 雀巢产品技术援助有限公司 | 植物乳杆菌cncm i‑4026制备物及其皮肤健康益处 |
TW201917206A (zh) * | 2017-10-20 | 2019-05-01 | 葡萄王生技股份有限公司 | 一種胚芽乳酸桿菌、組合物、培養方法及降尿酸、改善過敏及/或降血糖的用途 |
JP2019214548A (ja) * | 2018-04-24 | 2019-12-19 | 葡萄王生技股▲分▼有限公司 | 骨疾患を予防、治療又は軽減するための方法及び組成物 |
JP2020059694A (ja) * | 2018-08-16 | 2020-04-16 | 葡萄王生技股▲ふん▼有限公司 | 長寿促進のための、ラクトバチルス・プランタルムgkm3の活性物質、それを含む組成物、およびその使用 |
JP2020080861A (ja) * | 2018-11-21 | 2020-06-04 | 葡萄王生技股▲ふん▼有限公司 | ラクトバチルスファーメンタムgkf3、それを含む組成物及び精神失調を改善する適用 |
WO2020106099A1 (ko) * | 2018-11-22 | 2020-05-28 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
Non-Patent Citations (2)
Title |
---|
PHARMACEUTICAL BIOLOGY, vol. 53, no. 3, JPN6022036723, 2015, pages 350 - 358, ISSN: 0004963888 * |
PROBIOTICS AND ANTIMICROBIAL PROTEINS, vol. 12, no. 1, JPN6022036724, 2019, pages 125 - 137, ISSN: 0004963889 * |
Also Published As
Publication number | Publication date |
---|---|
JP7297021B2 (ja) | 2023-06-23 |
TW202218677A (zh) | 2022-05-16 |
US20220152129A1 (en) | 2022-05-19 |
US11766465B2 (en) | 2023-09-26 |
TWI825362B (zh) | 2023-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10449222B2 (en) | Method for preventing and/or treating infections, colonisations, or illnesses related to Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pyogenes, Enterococcus faecium, Enterobacter cloacae, Proteus mirabilis, Bacteroides fragilis, Staphylococcus epidermidis, Propionibacterium acnes, Candida albicans and/or Malassezia furfur | |
JP2018115168A (ja) | プロバイオティクス細菌 | |
US20150104496A1 (en) | Composition containing at least one nutrivite, at least one disinfecting or decontaminating, and/or at least one protease-inhibiting active compound and/or active compound complex | |
JP7297021B2 (ja) | 乳酸菌発酵産物含有外傷外用組成物 | |
JP6741595B2 (ja) | プロバイオティック細菌の抗菌性溶解物 | |
MXPA06001167A (es) | Lactobacilo novedoso, preparacion del lactobacilo activante para un cuerpo vivo y agente preventivo o terapeutico para la infeccion de un cuerpo v | |
US8703205B2 (en) | Natural compositions and methods of promoting wound healing | |
HUE027565T2 (en) | New procedure for the production of Lactobacillus reuteri strain for medical and veterinary prevention and treatment | |
Zahedi et al. | Comparison of the effects of Lactobacillus brevis and Lactobacillus plantarum on cutaneous wound healing in rats | |
KR100871837B1 (ko) | 피부염 발병 억제, 피부 창상의 치유 촉진효과를 가지는미생물 배양물 및 그것들을 이용한 제품 | |
CN102105177A (zh) | 治疗皮肤损伤的药物组合物、敷料和方法,用于制备所述敷料的中间组合物和方法,以及与胶原基质缔合的铈盐的用途 | |
Meng et al. | Reclamation of herb residues using probiotics and their therapeutic effect on diarrhea | |
Rahimzadeh et al. | Comparison of two types of gels in improving burn wound | |
CN114470007A (zh) | 含乳酸菌发酵产物之创伤外用组合物及其用途 | |
CN107184964A (zh) | 一种医用防护剂及其制备方法和应用 | |
Salmah et al. | Synergistic effects of alcoholic extract of sweet basil (Ocimum basilicum L.) leaves and honey on cutaneous wound healing in rats | |
JPH07108857B2 (ja) | 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤 | |
Mahmood et al. | Evaluation of in vivo wound healing activity of Chromolaena odorata leaf extract on excision wounds model in rats | |
CN110585272A (zh) | 一种抑菌除疤液及其制备方法 | |
Wainwright | Biological control of microbial infections and cancer in humans: Historical use to future potential | |
TW201946642A (zh) | 用於皮膚傷口癒合之大豆醱酵組合物及其製備方法 | |
CN114832151A (zh) | 一种新型益生菌液体创可贴及其制备方法 | |
WO2023118327A1 (en) | Live bacteria as excipients for proteins | |
JP2017128522A (ja) | 創傷治癒促進組成物 | |
PL240628B1 (pl) | Sposób wytwarzania i pozyskiwania herbacianej błony celulozowej oraz fermentowanego roztworu alkoholowego z grzyba herbacianego do pielęgnacji i leczenia uszkodzeń skóry, w tym błon śluzowych |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230328 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230515 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7297021 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |